Nutriband Advances Abuse-Deterrent Transdermal Drug Technology with AVERSA Platform

Nutriband Inc., a pharmaceutical development company, is making significant strides in creating safer transdermal drug delivery systems through its innovative AVERSA technology. The technology represents a critical advancement in pharmaceutical safety, specifically targeting the prevention of drug abuse and accidental exposure in transdermal patches.

The AVERSA platform can be integrated into any transdermal patch and incorporates aversive agents designed to discourage misuse, diversion, and unintended exposure. This approach is particularly crucial in the context of opioid medications like fentanyl, which have a high potential for abuse.

The company has secured robust intellectual property protection for its technology, with patents granted across multiple international jurisdictions, including the United States, Europe, Japan, Korea, Russia, Canada, Mexico, Australia, and China. This extensive patent portfolio underscores the innovative nature and potential widespread applicability of the AVERSA technology.

Recent financial and strategic developments demonstrate Nutriband's commitment to bringing this technology to market. In April 2024, the company successfully closed an $8.4 million financing round specifically aimed at supporting the commercial development of AVERSA Fentanyl. Furthermore, in February 2025, Nutriband formalized a long-term exclusive partnership with Kindeva Drug Delivery to facilitate the pathway to market for its abuse-deterrent fentanyl transdermal patch.

The potential impact of AVERSA technology extends beyond individual drug safety. By creating a mechanism that can be incorporated into existing transdermal patch technologies, Nutriband offers a scalable solution to a critical public health challenge. The technology aims to balance patient access to necessary medications with robust safeguards against potential misuse.

As the pharmaceutical industry continues to grapple with the complexities of pain management and opioid safety, Nutriband's AVERSA technology represents an innovative approach to addressing these challenges. By developing a versatile platform that can be applied across various transdermal medications, the company is positioning itself at the forefront of pharmaceutical safety innovation.